カイジェンは、大正製薬とこの独占的ライセンス契約を締結しました。これは、同社の次世代自己免疫疾患治療薬「KG006」の開発および、特に日本における商業化を支援することを目的としています。つまり、基本的にはこの契約に基づき……
Sysmex Corporation and Gaudi Clinical Inc., have signed an agreement. This agreement…
Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co.,…
Asada Ladies Clinic and IBM Japan announced that they had jointly developed…
Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop…
Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and…
AGC Biologics, your friendly CDMO expert, announced a multiphase partnership with Novelty…
Nikon CeLL Innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation, has…
Sysmex Corporation and Gaudi Clinical Inc., have signed an agreement. This agreement…
Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co.,…
Asada Ladies Clinic and IBM Japan announced that they had jointly developed…
Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop…
Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and…
AGC Biologics, your friendly CDMO expert, announced a multiphase partnership with Novelty…
Nikon CeLL Innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation, has…
アカウントにサインインする